Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.32 |
| ▸ | DUSP10 | Q9Y6W6 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | S100A4 | P26447 | 1/20 | 0.31 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.31 |
| ▸ | PADI1 | Q9ULC6 | 1/20 | 0.31 |
| ▸ | PADI3 | Q9ULW8 | 1/20 | 0.31 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.31 |
| ▸ | PADI2 | Q9Y2J8 | 1/20 | 0.31 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13647921 | 1.00 | CYP19A1 (0.32) | CYP19A1TBXAS1DUSP10MAPTNPC1 | |
| SCHEMBL12895160 | 0.90 | L3MBTL1 (0.35) | CYP19A1TBXAS1MAPTNPC1ATG4B | |
| SCHEMBL6100191 | 0.77 | LMNA (0.44) | CYP19A1TBXAS1SMN1; SMN2KDM4E | |
| SCHEMBL6100187 | 0.77 | LMNA (0.44) | CYP19A1TBXAS1SMN1; SMN2KDM4E | |
| SCHEMBL13652914 | 0.76 | CYP19A1 (0.38) | CYP19A1TBXAS1DUSP10MAPTNPC1 | |
| SCHEMBL22579802 | 0.74 | TDP1 (0.42) | CYP19A1TBXAS1DUSP10MAPTTP53 | |
| SCHEMBL4017991 | 0.72 | HRH1 (0.40) | KDM4E | |
| SCHEMBL13647908 | 0.72 | HRH1 (0.40) | KDM4E | |
| SCHEMBL1855861 | 0.72 | ADRA1A (0.41) | MAPTNPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL1855529 | 0.72 | ADRA1A (0.41) | MAPTNPC1TP53RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598417-B2 | Analgesics; muscular disorders; diarrhea | ALLERGAN, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ADRB2, ADRA2A, ADRA2C | CYP19A1 3160/4885TBXAS1 594/4885DUSP10 3764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.